GU Cancer Clinical Trials

DISCLAIMER: All content found on cua.org is provided for information and education purposes. The medical information and clinical trials information is not intended to substitute for the advice of a physician, nor is it intended to provide legal advice. You should always consult your doctor for specific information on personal health matters, or other relevant professionals to ensure that your own circumstances are considered.

The CUA is not responsible in any manner for direct, indirect, special or consequential damages caused and/or arising from your use of cua.org.

Subspecialty
Renal | QC | Recruiting
MK-6482-011
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Merck Sharp & Dohme LLC
Start Date: February 25, 2021

NCT #: NCT04586231

SPONSOR: Merck Sharp & Dohme LLC & Eisai

INFO: https://clinicaltrials.gov/ct2/show/NCT04586231?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=13

CONTACT:

CISSS de la Monteregie-Centre: Greenfield Park, Quebec
Contact: 450-466-5000 x 3226
                                                             
CHU de Quebec Universite Laval: Quebec City, Quebec                                 
 418-525-4444 x 67712
                                                           
CHUS - Centre Hosp. Univ. Sherbrooke: Sherbrooke, Quebec                      
819-346-1110 x 12811                                                   
 

OTHER CANADIAN CENTRES: 

Greenfield Park, Quebec 

Quebec City, Quebec

Sherbrooke, Quebec

Bladder | ON | Recruiting
NAUTICAL
Neoadjuvant Upper Tract Invasive Cancer Trial
Dr. Girish Kulkarni
Start Date: February 8, 2021

NCT #: NCT04574960

SPONSOR: UHN in collaboration with Bladder Cancer Canada

INFO: https://clinicaltrials.gov/ct2/show/NCT04574960?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=1

CONTACT:  Sarah Cheung (437) 335-2949

Prostate | ON | Recruiting
IGPC-5
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy (IGPC-5)
Dr. Glen Bauman
Start Date: February 4, 2021

NCT #: NCT04053842

SPONSOR: London Health Sciences Centre

INFO: https://clinicaltrials.gov/ct2/show/NCT04053842

CONTACT: Catherine Hildebrand // 519-685-8500 ext 53535

Renal | AB, ON, QC | Recruiting
SOCRATIC
Surveillance of Complex Renal Cysts - The SOCRATIC Study (SOCRATIC)
Universite de Sherbrooke in collaboration with CIHR
Start Date: February 2, 2021

NCT #: NCT04558593

SPONSOR: Universite de Sherbrooke in collaboration with CIHR

INFO: https://clinicaltrials.gov/ct2/show/NCT04558593?term=SOCRATIC+BOSNIAK&draw=2&rank=2

CONTACT: amelie.tetu.ciussse-chus@ssss.gouv.qc.ca

OTHER CANADIAN CENTRES: 

Prostate Cancer Centre (Calgary): Dr. B. Bhindi                                                        
St. Joseph's Healthcare (Hamilton): Dr. A. Kapoor                                                
The Ottawa Hospital (Ottawa): Dr. L. Lavallee                                                     
Princess Margaret Hospital (Toronto): Dr. A. Finelli                                         
Centre intégré de santé et de services sociaux de Chaudière-Appalache (Levis QC): Dr. M. Gratton                                                                
CHUM (Montrael): Dr. JB Lattouf 
McGill University Health Centre (Montreal): Dr. S. Tanguay 
CHU de Quebec - Universite Laval (Quebec City): Dr. F. Pouliot                                               
Centre de recherche du Centre hospitalier Universitaire de Sherbrooke (Sherbrooke): Dr. P.O. Richard
 

Bladder | AB, ON | Recruiting
RADIANT
Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)
Dr. Michael Ong
Start Date: January 29, 2021

NCT #: NCT04543110

SPONSOR: Ottawa Hospital Research Institute in collaboration with: Cross Cancer Institute, Hamilton Health Sciences Corporation, London Health Sciences Centre, Ontario Institute for Cancer Research, AstraZeneca, Ozmosis Research Inc.

INFO: https://clinicaltrials.gov/ct2/show/NCT04543110?recrs=abf&cond=Urothelial+Carcinoma&cntry=CA&draw=2&rank=10

CONTACT: 613-737-7700 ext 70179

OTHER CANADIAN CENTRES:

1. Cross Cancer Institute (Edmonton): 780-432-8248                                                            
2. Ottawa Hospital Cancer Centre (OHRI): 613-737-7700 ext 70179                              
3. Juravinski Cancer Centre (Hamilton): lalania@HHSC.CA                                                   
4. London Health Sciences Centres (London): 519-685-8600
 

Prostate | BC, ON, QC | Recruiting
PATRON
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer (PATRON)
Cynthia Menard
Start Date: January 6, 2021

NCT #: NCT04557501

INFO: https://clinicaltrials.gov/ct2/show/NCT04557501

CONTACT:  514-890-8254

Prostate | AB, BC, NS, ON, QC | Active, not recruiting
PROpel
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Dr. Fred Saad
Start Date: January 6, 2021
Prostate | ON | Recruiting
SHARP
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
Dr. Mark Corkum
Start Date: December 23, 2020

NCT #: NCT04861415

SPONSOR: Sunnybrook Health Sciences Centre

INFO: https://clinicaltrials.gov/ct2/show/NCT04861415

CONTACT:  416-480-6100 ext 6165

Renal | ON, QC | Recruiting
MK-3475-03B
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Start Date: December 17, 2020

NCT #: NCT04626518

SPONSOR: Merck Sharp & Dohme LLC

INFO:  https://clinicaltrials.gov/ct2/show/NCT04626518?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=16

CONTACT:

Princess Margaret Cancer Centre (Toronto): 416-946-4501 x 5606          

Jewish General Hospital (Montreal): 514-340-8222 x 24572

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto)                                        

Jewish General Hospital (Montreal)                                              

Renal | ON, QC | Recruiting
MK-3475-03A
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Start Date: December 16, 2020

NCT #: NCT04626479

SPONSOR: Merck Sharp & Dohme LLC

INFO:  https://clinicaltrials.gov/ct2/show/NCT04626518?recrs=abf&cond=Renal+Cell+Carcinoma&cntry=CA&draw=2&rank=16

CONTACT: 

Princess Margaret Cancer Centre (Toronto): 416-946-4501 x 5606          

Jewish General Hospital (Montreal): 514-340-8222 x 24572

OTHER CANADIAN CENTRES:

Princess Margaret Cancer Centre (Toronto), Jewish General Hospital (Montreal)

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org

Privacy Policy